€15.7 million Series B round secured
This round was led by Rejuveron Life Sciences and Vesalius Biocapital. The funding is being used to accelerate the clinical development of RJx-01.
Preclinical data reviewed by Scientific Advisory Board
The SAB concluded that the preclinical data of RJx-01 demonstrate proof-of-principle for sarcopenia, and show potential in multiple other muscle- and non-muscle-related disorders.
Committed to a sustainable future
After identifying 5 core Sustainable Development Goals, Rejuvenate Biomed defined company actions to reach these goals for a sustainable future.
Dr. Ajit Shetty appointed as Chair of the Board
Rejuvenate Biomed appoints Dr. Ajit Shetty as Chair of the Board of Directors. As a veteran of the life sciences industry, Dr. Shetty will strengthen the business strategy of this ambitious company through both mentorship and connections.
€3.2 million Series A round secured
Rejuvenate Biomed will use the funding to advance the development of lead candidate RJx-01 in both chronic and acute sarcopenia. The round was led by Vesalius Biocapital III.